KRM Ayurveda Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹35 Cr +40.7% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
KA

KRM Ayurveda Ltd

Q4 FY26Pharmaceuticals & Biotechnology

KRM Ayurveda Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹32Cr
+36% QoQ
Net profit
₹8Cr
+87.3% QoQ
Margin
34.09%
+5.7 pp QoQ

What the Q4 FY26 call signalled

3 of 3 strong

RevenueStrong growth
MarginMargins up
CapexCapex planned
Price₹303
Market cap₹664 Cr
P/E26.4

The short version

KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.

From KRM Ayurveda Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Strong growth
  • KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years.
  • Growth drivers include adding approximately 1,500 to 2,000 beds over the next three years across India.
  • Plans to open around 100 super-specialty clinics within three years, enhancing disease-specific treatments and increasing patient inflow.
  • Expansion includes 30 new clinics in the current year and increasing bed capacity from ~235 to 500 beds by year-end.
  • Telemedicine expansion with a new 500-seater center to double revenue from products and services.
  • Product sales will grow alongside clinic and hospital expansion, supported by e-commerce launches.

2 more points from KRM Ayurveda Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what KRM Ayurveda Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).
  • Expansion plans include adding 1500 to 2000 beds pan-India and opening about 100 super-specialty clinics over the next three years (Page 15).
  • Expect to increase bed capacity from 235 to 500 beds in FY27, with finalized agreements for additional 100-bed hospital in Gurgaon (Page 15).
  • Building a 500-seater telemedicine center operational in 1 to 1.5 years to support expansion (Page 22).
  • New luxury hospital of 25 beds being developed in Delhi, with scope for expansion (Page 13).

2 more points from KRM Ayurveda Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what KRM Ayurveda Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what KRM Ayurveda Ltd said on order book & pipeline — free account, 30 seconds.

KRM Ayurveda Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

KRM Ayurveda Ltd Q4 FY26 results — key figures

KRM Ayurveda Ltd Q4 FY26 reported results vs year-ago quarter, ₹ crore
₹ CrQ4 FY26Q2 FY26QoQ
Revenue3224+36%
Operating profit (EBITDA)117+63.2%
Operating margin34.09%28.41%+5.7 pp
Profit before tax106+83.3%
Net profit (PAT)84+87.3%
EPS (₹)3.672.69+36.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹35 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What KRM Ayurveda's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

KRM Ayurveda Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were KRM Ayurveda Ltd Q4 FY26 results?

KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.

What is KRM Ayurveda Ltd share price analysis?

KRM Ayurveda Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 26.4 with a market cap of ₹664 Cr. Investors should review the full earnings analysis for detailed insights.

Is KRM Ayurveda Ltd planning capital expenditure?

Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).

Keep KRM Ayurveda Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.